Minias (Lormetazepam)

Lormetazepam binds to the benzodiazepine site on the GABA‑A receptor complex, enhancing the effect of the inhibitory neurotransmitter GABA. This increases chloride ion flow into neurons, producing a calming effect that reduces brain activity and facilitates sleep.

The appropriate dose of Minias is determined by the prescribing clinician based on the patient’s age, health status, and severity of insomnia. The prescriber will select the lowest effective dose and limit the duration of therapy to minimise the risk of dependence.

Safety of lormetazepam in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified health professional.

To request Minias, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minias (lormetazepam) belongs to the benzodiazepine class, offering rapid onset of sleep and a short half‑life, which can be advantageous over longer‑acting agents that may cause residual daytime sedation. Compared with non‑benzodiazepine hypnotics, it has a similar efficacy but a higher potential for dependence, so it is typically reserved for short‑term use.

Minias tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Minias is taken orally, usually shortly before bedtime. The tablet should be swallowed whole with a glass of water and not chewed or crushed. Patients should follow the dosing instructions provided by their prescriber and avoid taking additional doses if sleep is not achieved.

The most serious risks include the development of physical or psychological dependence, withdrawal seizures upon abrupt discontinuation, severe respiratory depression when combined with other CNS depressants, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially during long‑term use.

Minias is contraindicated in individuals with known hypersensitivity to lormetazepam or any benzodiazepine, patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are currently abusing alcohol or other central nervous system depressants. It should also be used with extreme caution in the elderly and in patients with significant hepatic or renal impairment.